Healthcare

TradingKey - Amgen’s latest Sjögren’s trial success adds to its pipeline, while Repatha growth and MariTide trials shape the AMGN stock outlook for 2026.

Amgen rebounds to $410.24 as dazodalibep and IMDELLTRA strengthen the pipeline while $418.73 becomes the next technical test.

TradingKey - On September 21, US-listed stocks tied to Greenland resources surged in pre-market trading. Greenland Energy (GLND) soared over 220% at one point, Greenland Mines (GRML) rose by nearly 130% at its peak, and Critical Metals (CRML) surged more than 37%. Market attention is refocusing on Greenland's resource development potential, with the sharp rally in related stocks linked to a recent security agreement reached among the United States, Denmark, and Greenland.

TradingKey - On Monday, September 21, Eastern Time, futures on the three major US stock indices all rose in pre-market trading as high-level US-China talks sent positive signals. Meanwhile, Brent crude fell for the fourth consecutive trading session, temporarily easing market concerns over energy prices driving inflation.

TradingKey - On September 21, Novo Nordisk (NVO) shares fell more than 7% in US pre-market trading at one point. The company's latest financial results showed that while its full-year sales and profit guidance improved from previous forecasts, sales performance of its core weight-loss drug Wegovy still fell short of market expectations, becoming the primary factor weighing on the stock.

TradingKey - As Capital Markets Day approaches, Novo Nordisk (NVO) is facing mounting pressure from institutional investors.